Sorrento Therapeutics, Inc. 13D and 13G filings for Scilex Holding Company:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-09-26 4:49 pm Sale |
2023-09-21 | 13D | Scilex Holding Company SCLX |
Sorrento Therapeutics Inc. SRNEQ |
54,777 1.300% |
-2,674,751 (-97.99%) |
Filing |
| 2023-08-14 8:59 pm Unchanged |
2023-08-07 | 13D | Scilex Holding Company SCLX |
Sorrento Therapeutics Inc. SRNEQ |
2,729,529 43.300% |
0 (Unchanged) |
Filing |
| 2023-03-03 09:10 am Unchanged |
2023-02-21 | 13D | Scilex Holding Company SCLX |
Sorrento Therapeutics Inc. SRNEQ |
2,729,529 44.200% |
0 (Unchanged) |
Filing |
| 2023-01-23 4:33 pm Sale |
2023-01-19 | 13D | Scilex Holding Company SCLX |
Sorrento Therapeutics Inc. SRNEQ |
2,729,529 45.500% |
-2,067,262 (-43.10%) |
Filing |
| 2022-11-17 5:09 pm Purchase |
2022-11-10 | 13D | Scilex Holding Company SCLX |
Sorrento Therapeutics Inc. SRNEQ |
4,796,791 96.300% |
4,796,791 (New Position) |
Filing |